SPOTLIGHT -
Multiple Myeloma: Unmet Needs and Future Perspectives
Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.
Patient Profile 3: Patient With MM Progressing After Several Prior Therapies
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider use of CAR T-cell therapy or bispecifics in this setting.
Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma
The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.
CAR T-Cell Therapy in Multiple Myeloma and Quality of Life
A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.
Expert Highlights Tolerability and Safety of Ziftomenib in Phase 1 Trial
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
Treatment Approaches for Early Breast Cancer Progression
Paolo Tarantino, MD, explains his approach to treating patients with triple-negative breast cancer who progress early after completing adjuvant therapy.
Antibody-Drug Conjugates in TNBC: ASCENT and DESTINY-Breast04
An overview of antibody-drug conjugates in the recurrent triple-negative breast cancer treatment landscape, and the ASCENT and DESTINY-Breast04 trials.
Management of Bispecific Toxicities and Final Thoughts on Treatments in MM
Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.
The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options
Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.
Ziftomenib Elicits Responses in Relapsed/Refractory AML Mutation Subgroups
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
Expert Outlines KOMET-001 Trial Design Assessing Ziftomenib in AML
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.
Considerations For ADT Selection And Patient Education on Treatment-Related AEs
Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.
Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT
Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.
A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation
Joelle Hamilton, MD, reflects on strategies used in oncology practice to mitigate cardiovascular risk in patients with prostate cancer.
A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation
Insight is provided on strategies that may be employed to mitigate cardiovascular risk in patients receiving care for prostate cancer.
Future of Myeloma Treatment ‘Quite Exciting’ With New Immunotherapies
Luciano J. Costa, MD, PhD, discussed the future treatments being evaluated for the treatment of multiple myeloma.
Tumor-Naïve vs Tumor-Informed ctDNA Analyses in CRC Biomarker Testing
Dr Daniel H. Ahn explains the logistical concerns of ctDNA testing in colorectal cancer.
Circulating Tumor DNA and its Use in Colorectal Cancer Treatment Decision-Making
Aparna Parikh, MD, MS, defines circulating tumor DNA (ctDNA) and the use of ctDNA assays in colorectal cancer.
Receiving a Diagnosis of RCC: Patient and Caregiver Perspectives
Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.
An Expert Overview of Renal Cell Carcinoma
Expert oncologist Hans Hammers, MD, PhD, spearheads an overview on renal cell carcinoma, covering its current incidence and known risk factors.
